NBIX
Neurocrine Biosciences
Data as of 2026-10-14
Company attributes
Price
Interactive 5-year price history chart for NBIX. Latest close $141.37.
Pillar breakdown
0–100 percentile rank against the current universe (sector-relative for Quality / Value / Growth / Profitability)
- QualityProfit margins & asset efficiency80ExceptionalHealth Care median (n=163) 51
- ValuePrice vs fundamentals58StrongHealth Care median (n=163) 52
- GrowthRevenue & earnings trajectory85ExceptionalHealth Care median (n=163) 50
- MomentumRecent price strength47AverageHealth Care median (n=163) 66
- HealthBalance sheet & solvency64StrongHealth Care median (n=163) 56
- ProfitabilityROE, ROA, ROIC84ExceptionalHealth Care median (n=163) 49
- TechnicalTrend & volatility signals50AverageHealth Care median (n=163) 57
- RiskVolatility & drawdown profile48AverageHealth Care median (n=163) 47
Pillars not shown: Sentiment, ML (Phase 5+).
Fair price check
6 different valuation methods each estimate what NBIX should be worth, then we compare to today's price.
- EV/EBITDAUndervaluedthinks it's a bargain — estimates $229.83, about 63% above today
- P/B multiplesUndervaluedthinks it's a bargain — estimates $209.41, about 48% above today
- P/E multiplesUndervaluedthinks it's a bargain — estimates $179.21, about 27% above today
- DCF (2-stage)Overvaluedthinks it's expensive — estimates $49.26, about 65% below today
- Graham (defensive)Outlierestimate looks unreliable — estimates $27.28 — likely unreliable
- Residual IncomeOutlierestimate looks unreliable — estimates $10.65 — likely unreliable
How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.
Fair price ensemble
- Median fair
- $114.23
- Margin of safety(vs fair value)
- -23.8%
- Max (ex-outliers)
- $229.83
- Tangible BVPS
- $9.51
- Goodwill-heavy balance sheet
- Extreme Graham estimate
- Extreme Residual-Income estimate
Median of all applicable methods (current price $141.37). Per-method estimates + each method’s cheap/fair/pricey read are in the Fair price check above. Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.
Defense layer. Flags mark elevated risk, never confirmed fraud. This model cannot catch every manipulation and decays after publication — weigh it against its stated error rates.
Supporting dataRaw fundamentals & data-quality provenance behind the scores above
Raw fundamentals (SEC EDGAR)
| Metric | Value |
|---|---|
| Market cap | $14.37B |
| Revenue (TTM) | $3.37B |
| Net income (TTM) | $705.50M |
| Operating cash flow (TTM) | $898.10M |
| CapEx (TTM) | $42.60M |
| Free cash flow (TTM)CFO − CapEx | $855.50M |
| Total assets | $5.36B |
| Total liabilities | $1.67B |
| Stockholders' equity | $3.69B |
| Cash & equivalents | $332.40M |
| Shares outstanding | 101.65M |
| EPS (basic) | $6.94 |
| EPS (diluted) | $6.94 |
| P/E ratio (TTM) | 20.37 |
TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).
Data quality
- Latest filed date
- 2026-07-31
- Latest period end
- 2026-07-22
- Filing lag
- 75 days
- Missing metrics
- 6(gross_profit, research_and_development, interest_expense, dividends_paid, long_term_debt, short_term_debt)
Composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars are reserved for a later phase; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.